Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution